Pulmonary Hypertension: How to Best Treat the Different Scleroderma Phenotypes?

[1]  D. Stover,et al.  Iron therapy as a novel treatment of scleroderma‐related pulmonary hypertension: A case report and literature review , 2022, Respirology case reports.

[2]  Maynara Santana-Gonçalves,et al.  Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies , 2021, Frontiers in Medicine.

[3]  P. Hassoun.  Pulmonary Arterial Hypertension. , 2021, The New England journal of medicine.

[4]  P. Ponikowski,et al.  Empagliflozin in Heart Failure with a Preserved Ejection Fraction. , 2021, The New England journal of medicine.

[5]  S. Rosenkranz,et al.  Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. , 2021, The Lancet. Respiratory medicine.

[6]  A. Sweatt,et al.  Safety and Efficacy of B-Cell Depletion with Rituximab for the Treatment of Systemic Sclerosis Associated Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Randomized, Placebo-controlled Trial. , 2021, American journal of respiratory and critical care medicine.

[7]  S. Nathan,et al.  Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease. , 2021, The New England journal of medicine.

[8]  R. Benza,et al.  Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension , 2020, Chest.

[9]  J. Pope,et al.  Factors associated with pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc). , 2020, Autoimmunity reviews.

[10]  M. Majdan,et al.  Haematological abnormalities in systemic sclerosis , 2020, Reumatologia.

[11]  Matthew R. Neville,et al.  Individuals With Scleroderma May Have Increased Risk of Sleep-Disordered Breathing. , 2019, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[12]  F. Lombardi,et al.  Cardiopulmonary exercise testing in a combined screening approach to individuate pulmonary arterial hypertension in systemic sclerosis , 2019, Rheumatology.

[13]  H. Collard,et al.  Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. , 2019, The Lancet. Respiratory medicine.

[14]  A. Torbicki,et al.  Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension. , 2019, Seminars in arthritis and rheumatism.

[15]  H. Olschewski,et al.  Potential role of exercise echocardiography and right heart catheterization in the detection of early pulmonary vascular disease in patients with systemic sclerosis , 2019, Journal of scleroderma and related disorders.

[16]  D. Badesch,et al.  Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report , 2019, Chest.

[17]  A. Torbicki,et al.  Diagnosis of pulmonary hypertension , 2019, European Respiratory Journal.

[18]  M. Humbert,et al.  Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives , 2019, European Respiratory Journal.

[19]  Z. Jing,et al.  Risk stratification and medical therapy of pulmonary arterial hypertension , 2019, European Respiratory Journal.

[20]  Paul G. Williams,et al.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension , 2019, European Respiratory Journal.

[21]  S. Söderberg,et al.  A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension , 2018, European heart journal.

[22]  V. Steen,et al.  Long‐Term Outcomes in Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS) , 2018, Chest.

[23]  M. Khan,et al.  Is Anticoagulation Beneficial in Pulmonary Arterial Hypertension?: A Systematic Review and Meta-Analysis , 2018, Circulation. Cardiovascular quality and outcomes.

[24]  A. Waxman,et al.  Assessment of the quality of anticoagulation management in patients with pulmonary arterial hypertension. , 2017, Thrombosis research.

[25]  C. Denton,et al.  SYSTEMIC SCLEROSIS , 2008 .

[26]  M. Humbert,et al.  Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension , 2017, European Respiratory Journal.

[27]  H. Ghofrani,et al.  Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension , 2017, European Respiratory Journal.

[28]  C. Hill,et al.  Epidemiology and disease characteristics of systemic sclerosis-related pulmonary arterial hypertension: results from a real-life screening programme , 2017, Arthritis Research & Therapy.

[29]  A. Swift,et al.  Idiopathic and Systemic Sclerosis‐Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes , 2017, Chest.

[30]  E. A. Sykes,et al.  Hypoxic Pulmonary Vasoconstriction: From Molecular Mechanisms to Medicine , 2017, Chest.

[31]  M. Humbert,et al.  Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2 , 2016, Annals of the rheumatic diseases.

[32]  J. Barberà,et al.  Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial , 2015, Annals of the rheumatic diseases.

[33]  C. Denton,et al.  Gastrointestinal manifestations of systemic sclerosis , 2016, Journal of scleroderma and related disorders.

[34]  Héctor Bueno,et al.  Guía ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensión pulmonar , 2016 .

[35]  Hyon K. Choi,et al.  Risk of Pulmonary Embolism and Deep Venous Thrombosis in Systemic Sclerosis: A General Population‐Based Study , 2016, Arthritis care & research.

[36]  Stefan L. Zimmerman,et al.  Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. , 2015, American journal of respiratory and critical care medicine.

[37]  L. Rajasekhar,et al.  Pulmonary arterial hypertension in systemic lupus erythematosus may benefit by addition of immunosuppression to vasodilator therapy: an observational study. , 2015, Rheumatology.

[38]  J. Barberà,et al.  Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. , 2015, The New England journal of medicine.

[39]  C. Băicuș,et al.  Association of anti phosphatidyl ethanolamine antibodies and low complement levels in systemic sclerosis patients – results of a cross-sectional study , 2015, Scandinavian journal of clinical and laboratory investigation.

[40]  P. Ponikowski,et al.  Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency† , 2014, European heart journal.

[41]  R. Benza,et al.  Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry , 2014, Chest.

[42]  M. Gladwin,et al.  Pulmonary arterial hypertension: the clinical syndrome. , 2014, Circulation research.

[43]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[44]  J. Wharton,et al.  Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. , 2014, Rheumatology.

[45]  S. Birring,et al.  Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. , 2014, American journal of respiratory and critical care medicine.

[46]  H. Heinzl,et al.  Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study , 2013, Annals of the rheumatic diseases.

[47]  C. Denton,et al.  Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. , 2013, Arthritis and rheumatism.

[48]  M. Hudson,et al.  High prevalence of occult left heart disease in scleroderma-pulmonary hypertension , 2012, European Respiratory Journal.

[49]  J. Vachiéry,et al.  Challenges in the diagnosis and treatment of pulmonary arterial hypertension , 2012, European Respiratory Review.

[50]  M. Humbert,et al.  Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension. , 2012, Arthritis and rheumatism.

[51]  D. Liew,et al.  N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study , 2012, Arthritis Research & Therapy.

[52]  M. Mayes,et al.  Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry , 2012, Annals of the rheumatic diseases.

[53]  M. Humbert,et al.  Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. , 2011, Arthritis and rheumatism.

[54]  V. Steen,et al.  Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study Population , 2011, The Journal of Rheumatology.

[55]  M. Baron,et al.  Associations with digital ulcers in a large cohort of systemic sclerosis: Results from the Canadian Scleroderma Research Group registry , 2011, Arthritis care & research.

[56]  J. Cracowski,et al.  Prevalence of Pulmonary Hypertension in Systemic Sclerosis in European Caucasians and Metaanalysis of 5 Studies , 2010, The Journal of Rheumatology.

[57]  H. Farber,et al.  Cardiopulmonary Exercise Testing with Right-heart Catheterization in Patients with Systemic Sclerosis , 2010, The Journal of Rheumatology.

[58]  H. Ghofrani,et al.  Updated classification and management of pulmonary hypertension , 2010, Heart.

[59]  Ami A. Shah,et al.  Telangiectases in Scleroderma: A Potential Clinical Marker of Pulmonary Arterial Hypertension , 2010, The Journal of Rheumatology.

[60]  P. Ponikowski,et al.  Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.

[61]  D. Playford,et al.  Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis , 2009, Internal medicine journal.

[62]  J. Vachiéry,et al.  Screening for pulmonary arterial hypertension in systemic sclerosis , 2009, European Respiratory Review.

[63]  Horst Olschewski,et al.  Diagnosis and assessment of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.

[64]  P. Hassoun.  Therapies for scleroderma-related pulmonary arterial hypertension , 2009, Expert review of respiratory medicine.

[65]  N. Lamblin,et al.  Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients , 2008, Annals of the rheumatic diseases.

[66]  W. Lehmacher,et al.  The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement , 2008, Rheumatology.

[67]  M. Humbert,et al.  Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. , 2008, Arthritis and rheumatism.

[68]  R. Barst,et al.  Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. , 2007, The Journal of rheumatology.

[69]  M. Humbert,et al.  Results of European post-marketing surveillance of bosentan in pulmonary hypertension , 2007, European Respiratory Journal.

[70]  T. Medsger,et al.  Changes in causes of death in systemic sclerosis, 1972–2002 , 2007, Annals of the rheumatic diseases.

[71]  M. Humbert,et al.  Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. , 2006, Chest.

[72]  M. Humbert,et al.  Pulmonary arterial hypertension in France: results from a national registry. , 2006, American journal of respiratory and critical care medicine.

[73]  S. Rich,et al.  Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. , 2004, Chest.

[74]  T. Medsger,et al.  Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. , 2003, Arthritis and rheumatism.

[75]  F. Saulnier,et al.  Aerosolized iloprost in CREST syndrome related pulmonary hypertension. , 2001, The Journal of rheumatology.

[76]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[77]  D. Badesch,et al.  Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.

[78]  A Giaid,et al.  Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.

[79]  D. Stewart,et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.